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Abstract
Background: Chronic kidney disease (CKD) has been linked to higher heart failure (HF) risk.
Anemia is a common consequence of CKD, and recent evidence suggests that anemia is a risk
factor for HF. The purpose of this study was to examine among patients with HF, the association
between CKD, anemia and inhospital mortality and early readmission.
Methods: We performed a retrospective cohort study in two Swiss university hospitals. Subjects
were selected based the presence of ICD-10 HF codes in 1999. We recorded demographic
characteristics and risk factors for HF. CKD was defined as a serum creatinine ≥ 124 956;mol/L for
women and ≥ 133 µmol/L for men. The main outcome measures were inhospital mortality and
thirty-day readmissions.
Results: Among 955 eligible patients hospitalized with heart failure, 23.0% had CKD. Twenty
percent and 6.1% of individuals with and without CKD, respectively, died at the hospital (p <
0.0001). Overall, after adjustment for other patient factors, creatinine and hemoglobin were
associated with an increased risk of death at the hospital, and hemoglobin was related to early
readmission.
Conclusion: Both CKD and anemia are frequent among older patients with heart failure and are
predictors of adverse outcomes, independent of other known risk factors for heart failure.
Background
Heart failure (HF) is a common and serious condition
that affects more than four million people in the United
States [1]. Approximately 400,000 new cases are diag-
nosed each year, with mortality 6 years after diagnosis of
80% in men and 65% in women [1]. In Europe, the prev-
alence of symptomatic heart failure in the general popula-
tion is estimated to range from 0.4% to 2% [2]. In
Switzerland, approximately 210,000 people have HF [3].
Chronic kidney disease (CKD) is also a major health
problem resulting in considerably increased morbidity,
mortality and in high costs [4]. Furthermore, in the last
decade, the prevalence of both CKD[5,6], and HF has
been rising steadily [7-9]. Anemia is a frequent complica-
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tion of chronic kidney disease, primarily due to failure of
erythropoietin production to respond to decreased hae-
moglobin concentration [10,11]. Anemia has also been
found to be a risk factor for cardiovascular disease and in
particular for HF [12,13]. In a study conducted in one
Swiss university hospital the prevalence of anemia among
heart failure patients was 15% [13].
Furthermore, several studies have also shown that anemia
with the presence of heart failure was a predictor of poor
outcome [14-20] and greater hospital expenses [21].
Moreover, two recent studies have shown that anemia
associated with CKD were independent risk factors for
one year mortality among patients with HF [22,23]. One
study included only patients with left ventricular systolic
dysfunction [22], whereas patients with left ventricular
diastolic dysfunction were also included in the other [23].
Independent associations between both CKD and anemia
with increased risk of one-year mortality were found. In
both studies, a 1% decrease in hematocrit was associated
with a 2.5% increase in the 12 month risk of death.
The purpose of our study was to examine, among patients
with HF, the combined association of CKD and anemia
on adverse outcomes. To our knowledge, this is the first
study using inhospital mortality and early readmission for
this purpose.
Methods
Study design
This was a retrospective cohort study of patients having a
diagnosis of heart failure hospitalized and discharged
between January 1- December 31, 1999 from two Swiss
university hospitals. All adult patients with heart failure
hospitalized in all wards for any reason were included in
the study. Outcome measures of interest were inhospital
mortality and 30-day readmissions. Follow-up for each
patient began on the date of discharge from the hospital
and continued for 30 days.
Population
Using administrative data, we identified all patients hos-
pitalized with a principal or secondary diagnosis of HF
(International Classification of Disease, 10th  revision:
Table 1: Patients Characteristics at Admission in Patients with Heart Failure and Proportion with Chronic Kidney Disease, N = 955
Characteristics N (%) Chronic Kidney Disease (%) * 
N (%)
Mean (SD) serum creatinine 
µmol/l
N (%) 955 (100.0) 220 (23.0) 113.9 (54.0)
Hospital A 411 (43.0) 109 (26.5) 116.4 (56.2)
Hospital B 544 (57.0) 111 (20.4)** 112.0 (52.3)
Age (N = 955)
16 – 60 years 114 (11.9) 23 (20.2) 111.4 (56.2)
61 – 70 years 172 (18.0) 33 (19.2) 110.2 (50.7)
71 – 80 years 282 (29.5) 61 (21.6) 113.2 (56.0)
> 80 years 387 (40.5) 103 (26.6) 116.7 (53.5)
Sex (N = 954)
Male 518 (54.3) 131 (25.3) 120.1 (55.4)
Female 436 (45.7) 89 (20.4) 106.5 (51.5)**
Previous history Heart Failure (N = 876) 514 (58.7) 126 (24.5) 115.6 (53.4)
Prior MI (N = 945) 322 (34.1) 84 (26.1) 119.2 (50.7)**
COPD, bronchitis, Emphysema (N = 944) 188 (19.9) 37 (19.7) 107.3 (45.8)**
Hypertension (N = 950) 577 (60.7) 144 (25.0) 117.8 (57.7)**
Diabetes (N = 952) 221 (23.2) 57 (25.8) 122.3 (58.4)**
Current smoker (N = 930) 141 (15.2) 25 (17.7) 104.7 (43.0)**
Symptoms and findings
PND (N = 608) 163 (26.8) 37 (22.7) 114.1 (50.1)
DOE (N = 849) 672 (79.2) 158 (23.5) 113.8 (50.9)
Orthopnea (N = 655) 330 (50.4) 92 (27.9)** 111.1 (56.4)
Leg edema (N = 791) 438 (55.4) 117 (26.7)** 118.0 (59.0)**
Pulmonary rales (N = 815) 508 (62.3) 124 (24.4) 115.0 (53.9)
S3 gallop (N = 757) 39 (5.2) 8 (20.5) 111.4 (32.6)
JVD (N = 700) 236 (33.7) 66 (28.0)** 118.2 (62.0)
Atrial fibrillation (N = 797) 221 (27.7) 54 (24.4) 110.0 (38.9)
MI: Myocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease; PND: Paroxystal Nocturnal Dyspnea; DOE: Dyspnea On Exertion; JVD: 
Jugular Vein Distension
* Chronic kidney disease (CKD) was defined as a serum creatinine > = 124 µmol/L for women and > = 133 µmol/L for men
** p value < 0.05BMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
Page 3 of 10
(page number not for citation purposes)
I50.0, I50.1, I50.9, I11.0, I13.0 and I13.2 (ICD-10)). We
then selected a random sample of 700 patients hospital-
ized in each hospital with HF among respectively 976 and
774. Patients were excluded from the sample if the initial
hospitalization was terminated against medical advice, or
if they were transferred to another acute care hospital or if
no information on the creatinine level was available.
Additional exclusion criteria included diagnosis of valvu-
lar heart disease, acute myocardial infarction, cor pulmo-
nale, chronic obstructive pulmonary disease treated with
home oxygen, thiamine deficiency, amyloidosis and thy-
rotoxicosis.
Data
Data were abstracted from medical charts by medical
record specialists. The entire medical chart was available
in one hospital and the scanned medical record was used
in the other. Variables abstracted from the chart included
age, sex, smoking status, recorded history of previous
heart failure, myocardial infarction, chronic obstructive
pulmonary disease, bronchitis, emphysema, hypertension
and diabetes. Clinical information included a history of
paroxysmal nocturnal dyspnea, dyspnea on exertion
(DOE) and orthopnea. Physical findings abstracted
included pedal edema, pulmonary rales, S3-gallop and
evidence of elevated jugular vein pressure. The presence of
atrial fibrillation on the admission electrocardiogram
(ECG) was recorded. Hemoglobin levels were distributed
in four groups: <10 g/dL, 10 g/dL to 12 g/dL, 12 g/dL to
14 g/dL, and ≥ 14 g/dL. The final serum creatinine values
recorded during the hospitalization were also considered.
Chronic kidney disease (CKD) was defined as a serum cre-
atinine ≥ 124 µmol/L for women and ≥ 133 µmol/L for
men. We choose these ranges because they were used pre-
viously in an US study, in order to be able to do compar-
isons of CKD prevalence between countries [23]. We did
not calculate creatinine clearance because, in many
patients, the information available in our data set did not
allow us to calculate it. A random replicate sample of 100
charts was abstracted to assess inter-rater reliability. The
Kappa estimate was 0.91 for the determination of the ven-
tricular function (VF) and 1.0 for inhospital mortality.
Information on inhospital mortality and readmission
within 30 days was gathered using administrative data
provided by the hospitals. We assessed all cause readmis-
sion and included only patients from the index hospital.
Because these hospitals are university referral centers, each
for a different area, we assumed that only few patients
could have been readmitted to a different hospital.
Indeed, for one provider, we could assess that none of the
patients were readmitted to another Swiss hospital using
a unique identifier from the Swiss Federal Statistical
Office.
The determination of the left ventricular function was
based on the chart by the presence of a value for a previ-
ously measured ejection fraction on echocardiography,
cardiac catheterization, radionuclide ventriculography or
by a narrative statement in the chart. Patients with left
ventricular systolic dysfunction (LVSD) were identified by
looking in medical charts for a current (from the index
hospitalization) or previous ejection fraction (EF) equal
or less than 40%. If no information regarding the EF was
found, we searched for a narrative description in the chart.
Specifically, the following terms were associated to LVSD:
"systolic dysfunction." "dilated cardiomyopathy," "con-
gestive cardiomyopathy," "diffuse global hypokinesis" or
"systolo-diastolic dysfunction" (patients reported to have
both systolic and diastolic dysfunction by cardiologists).
Further, angiotensin converting enzyme inhibitor (ACEI)
were identified in the medical charts through generic or
trade name, including benazapril, captopril, enalapril,
fosinopril, lisinopril, quinalapril, ramipril, perinopril and
cilazapril.
The Charlson co-morbidity index, a weighted average of
selected co-morbidities, was computed at index hospitali-
zation for each patient as a measure of severity of illness
measure using the Deyo modification [24].
Statistical analysis
Bivariate analyses of the dependent and the primary expo-
sure variables were conducted. We also calculated the
crude risk ratio and 95% confidence intervals for inhospi-
tal mortality and 30-day readmission. We used chi-square
tests, Fisher's exact tests, Student T-tests or ANOVA meth-
ods when appropriate. Dichotomous outcome variables
were inhospital mortality and readmission within 30
days. Primary exposure variables were hemoglobin and
creatinine levels. Other variables, potential confounding
factors, included in the bivariate analysis were: hospital,
age, sex, history of heart failure, diabetes mellitus, hyper-
tension, prior myocardial infarction, chronic obstructive
pulmonary disease, smoking, symptoms and findings at
admission (paroxysmal nocturnal dyspnea, dyspnea on
exertion, orthopnea, leg oedema, pulmonary rales, jugu-
lar vein distension, S3-gallop), atrial fibrillation, left ven-
tricular function, ejection fraction, ACEI prescription at
discharge, Charlson co-morbidity index, as well as inhos-
pital length of stay.
We then performed multivariate analyses using logistic
regression to adjust for potential confounding factors.
Logistic regression was used to calculate adjusted odds
ratio with associated 95% confidence intervals. Covariates
were initially selected using a priori considerations as well
as strength of association and statistical significance in
bivariate analyses. We included the variable "Left ven-
tricular function" in the starting model in order to controlBMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
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for the heterogeneity of the study population between
diastolic and systolic HF. We first looked if interaction
between hemoglobin and creatinine was significant. After
defining the starting model as above, we assessed, by
backward elimination, which confounding factors should
remain in the model. We first looked to see if the least sig-
nificant variable was a confounding factor by dropping it
and refitting the model. We then assessed if the odds ratio
changed by more than 10% compared to odds ratio of the
starting model. If the odds ratios changed by more then
10%, the variable was considered as a potential confound-
ing factor and remained in what became the final model.
If a variable did not meet these criteria, it was removed
from the model and the same procedures were reapplied
until the best final model was found. Fit of the models
was assessed using the Hosmer-Lemeshow goodness of fit
test. For all models, we checked for any potential colline-
arity problems between the variables. All analyses were
implemented with the SAS software, version 8.02 (SAS
Institute Inc. Cary, NC, USA).
Results
Baseline characteristics
Our sample included 955 eligible patients with HF avail-
able for analysis. Among those 411 (43.0%) were admit-
ted to hospital A and 544 (57.0%) in hospital B. The mean
(SD) age was 75.4 years (12.8), 45.7% were female. A his-
tory of HF was present in 58.7% of the patients. A history
of myocardial infarction was reported for 34.1%, hyper-
tension for 60.7%, diabetes for 23.2%, and COPD or
bronchitis or emphysema for 19.9%. At discharge, antico-
agulants were prescribed in 28.7% of the patients, beta-
blockers in 12.8%, calcium blockers in 13.3%, digoxin in
32.2%, diuretics in 59.9%, nitrates in 30.3%, angiotensin
receptor blockers in 8.1% and spironolactone in 11.1%.
In our sample, based on a value of left ventricular ejection
fraction or a narrative statement, 28.9% had their left ven-
tricular function not determined, 28.0% had a left ven-
tricular systolic dysfunction (LVSD), and 43.1% a left
ventricular diastolic dysfunction. Further, a report describ-
Table 2: Hospital Characteristics in Patients with Heart Failure and Proportion with Chronic Kidney Disease, N = 955
Characteristics N (%) Chronic Kidney Disease (%) * 
N (%)
Mean (SD) serum creatinine 
µmol/l
N (%) 955 (100.0) 220 (23.0) 113.9 (54.0)
Ejection fraction in % (N = 446)
< = 20 77 (17.3) 20 (26.0) 121.3 (45.1)
20–30 128 (28.7) 29 (22.7) 115.9 (65.2)
30–40 108 (24.2) 28 (25.9) 116.8 (49.2)
> 40 133 (29.8) 37 (27.8) 120.2 (63.5)
Left ventricular function (N = 955)
Diastolic dysfunction 412 (43.1) 98 (23.8) 115.7 (51.1)
Systolic dysfunction 267 (28.0) 61 (22.9) 116.6 (64.6)
Undetermined 276 (28.9) 61 (22.1) 108.5 (46.3)
Discharged with ACEI (N = 884) 541 (61.2) 109 (20.2) 108.1 (36.2)**
Charlson comorbidity index (N = 
955)
0–1 398 (41.7) 55 (13.8) 102.4 (38.5)
2 216 (22.6) 28 (13.0) 102.2 (40.0)
>2 341 (35.7) 137 (40.2)** 134.6 (69.1)**
Inhospital mortality (N = 955) 89 (9.3) 44 (49.4)** 159.3 (106.1)**
30 days readmissions (N = 866) 116 (13.4) 26 (22.4) 107.7 (38.7)
Length of stay (days) (N = 955)
0–6 247 (25.9) 58 (23.5) 118.3 (55.1)
7–12 321 (33.6) 69 (21.5) 112.6 (53.6)
>12 387 (40.5) 93 (24.0) 112.0 (53.7)
ACEI: Angiotensin Converting Enzyme Inhibitors
* Chronic kidney disease (CKD) was defined as a serum creatinine > = 124 µmol/L for women and > = 133 µmol/L for men
** p value < 0.05BMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
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ing previous or current value of left ventricular ejection
fraction was found in 46.7% of the patient's charts. The
mean (SD) ejection fraction was 36.0% (15.0%) with a
25th to 75th intraquartile range from 25 to 45%. An ACEI
was prescribed at discharge in 61.2% of the patients. The
mean (SD) Charlson comorbidity index was 2.2 (1.4).
The median length of stay was 10 days, with a 25th to 75th
intraquartile range from 6 to 17 days.
Prevalence of CKD
The mean (SD) value of the last serum creatinine value
reported during the hospitalization was 113.9 (54.0)
µmol/L, with a range from 32 to 545 µmol/L and a 25th to
75th intraquartile range from 84 to 126 µmol/L. Chronic
kidney disease was defined as a serum creatinine ≥ 124
µmol/L in women and ≥ 133 µmol/L in men. Men
(25.3%) were more likely than women (20.4%) to have
CKD. In total, 220 (23.0%) patients of the entire cohort
had CKD. The mean serum creatinine value was statisti-
cally significantly higher in patients with a history of myo-
cardial infarction, hypertension, diabetes or leg edema
(Table 1). Higher creatinine values were also observed in
patients with a Charlson comorbidity index larger than 2
(Table 2).
Prevalence of anemia
Hemoglobin level was recorded for 920 members (96%)
of the cohort. The mean (SD) hemoglobin was 13.0 g/dL
(2.2) with a 25th to 75th intraquartile range from 11.8 g/dL
to 14.6 g/dL. On admission, an hemoglobin of ≥ 14 g/dL
was found in 36.1% of the patients, 36.3% had an hemo-
globin between 12 g/dL and 14 g/dL, 19.6% between 10
g/dL and 12 g/dL, and 8% ≤ 10 g/dL.
The proportion of patients with CKD was associated with
increasing anemia (Table 3). The mean serum creatinine
was increasing with severity of anemia (Table 3) from
102.0  µmol/L among patients with no anemia, up to
141.0 µmol/L for severe anemia (p < 0.0001). Patients
with severe anemia were more likely not to be discharged
with ACEI. (Table 3).
Mortality and readmission
Eighty-nine (9.3%) patients died during their hospitaliza-
tion, 20% among those with CKD and 6.1% among those
without CKD (p < 0.0001). Among patients who died in
the hospital, 49.4% had CKD, and their mean (SD) serum
creatinine value was 159.3 µmol/L (106.1) (p < 0.0001).
Anemia on admission to the hospital was associated with
increased risk of death. In-hospital mortality was 5.4% for
patients with a hemoglobin of ≥ 14 g/dL, 9.3% for a
hemoglobin between 12 g/dL and 14 g/dL, 10.0% for a
hemoglobin between 10 g/dL and 12 g/dL, and 18.9% for
a hemoglobin < 10 g/dL (p = 0.002) (Table 3). In-hospital
mortality rates were also higher in patients with COPD
(Table 4) and in patients with a Charlson comorbidity
index over 2. Individuals with left ventricular diastolic
and systolic dysfunction, as well as those with undeter-
mined ventricular function, had comparable risk of hospi-
tal death (Table 5).
Among 866 patients discharged alive, 116 (13.4%) were
readmitted within 30 day, 14.0% of patients with CKD,
and 12.9% of those without CKD. Early readmission
occurred in 11.5% of patients with a hemoglobin of ≥ 14
g/dL, 12.5% for a hemoglobin between 12 g/dL and 14 g/
Table 3: Hospital Characteristics in Patients with Heart Failure According to Hemoglobin Level, N = 955
Hemoglobin in g/dL
<10 N (%) or 
Mean (SD)
10–12 N (%) or 
Mean (SD)
12–14 N (%) or 
Mean (SD)
≥14 N (%) or 
Mean (SD)
N (%) (N = 920) 74 (8.0) 180 (19.6) 334 (36.3) 332 (36.1)
CKD (N = 920)* 28 (37.8) 61 (33.9) 78 (23.4) 48 (14.5)
Mean (SD) serum creatinine (N = 920)* (µmol/L) 141.0 (91.0) 131.6 (76.5) 110.3 (42.5) 102.0 (30.7)
Left ventricular function (N = 920)*
Diastolic dysfunction 19 (25.7) 70 (38.9) 136 (40.7) 171 (51.5)
Systolic dysfunction 29 (39.2) 58 (32.2) 89 (26.7) 80 (24.1)
Undetermined 26 (35.1) 52 (28.9) 109 (32.6) 81 (24.4)
Mean (SD) ejection fraction in % (N = 429)* 41.8 (14.7) 39.7 (14.7) 35.9 (15.5) 34.1 (14.3)
Discharged with ACEI (N = 854)* 31 (45.6) 108 (63.2) 196 (63.2) 193 (63.2)
Hospital A (N = 406) 27 (6.7) 72 (17.7) 153 (37.7) 154 (37.9)
Hospital B (N = 514) 47 (9.1) 108 (21.0) 181 (35.2) 178 (34.6)
Inhospital mortality (N = 920)* 14 (18.9) 18 (10.0) 31 (9.3) 18 (5.4)
30 days readmissions (N = 839) 8 (13.3) 29 (17.9) 38 (12.5) 36 (11.5)
Mean (SD) length of stay (days) (N = 920)* 18.8 (21.3) 16.8 (16.4) 13.8 (17.0) 12.4 (9.5)
CKD: Chronic Kidney Disease; ACEI: Angiotensin Converting Enzyme Inhibitors
*p value < 0.05BMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
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dL, 17.9% for a hemoglobin between 10 g/dL and 12 g/dL
and 13.3% for a hemoglobin < 10 g/dL. Patients who were
current smokers and with COPD were also more likely to
be readmitted (Table 4).
Multivariate analysis
Both hemoglobin and serum creatinine were independ-
ently associated with poor outcomes after controlling for
confounding factors (Table 6). For inhospital mortality,
the model controlled for length of stay and COPD. For
each g/dL increase in hemoglobin, the inhospital mortal-
ity rate declined by 39% (p = 0.0008). For each one µmol/
L increase in serum creatinine, inhospital mortality rate
decreased by 1% (p = 0.166). Further, the interaction term
between hemoglobin and serum creatinine was statisti-
cally significant (p = 0.008). At the mean creatinine level,
increasing hemoglobin levels were associated with lower
mortality (RR = 0.86, for each unit increase in hemo-
globin). Effect modification, suggested a weaker associa-
tion of hemoglobin with mortality as creatinine levels
increased. Further, at the mean level hemoglobin, increas-
ing creatinine levels were associated with higher mortality
(RR = 1.015, for each unit increase in creatinine).
In the multivariate analysis using 30 days readmission as
dependent variable, we controlled for age, COPD and his-
tory of heart failure. The interaction term between hemo-
globin and serum creatinine was not statistically
significant. Results showed that for each one g/dL increase
in hemoglobin, readmission rate declined by 13% (p =
0.009). Further, for each one µmol/L increase in serum
creatinine, readmission rate increased by 0.08% (p =
0.744).
After controlling for all other risk factors, the odds ratio
related to inhospital mortality associated with the pres-
ence of anemia defined as hemoglobin less than 12 g/dL,
was 1.47 (95% CI 0.89 to 2.42) in all heart failure patients
and 4.04 (95% CI 2.46 to 6.66) in patients with addi-
tional CKD compared with HF patients who had a hemo-
globin level ≥ 12 g/dL and no CKD. Similarly, the odds
ratio for early readmissions were 1.60 (95% CI 1.00 to
Table 4: Patients Characteristics at Admission in Patients Hospitalized with Heart Failure by Outcome Indicators, N = 955
Inhospital mortality N = 955 30 day readmission N = 866
Patients Characteristics N N dead (%) 89 (9.3%) N N Readmitted (%) 116 (13.4%)
Hospital A 411 41 (10.0) 370 43 (11.6)
Hospital B 544 48 (8.8) 496 73 (14.7)
Age (N = 955)
16 – 60 years 114 7 (6.1) 107 18 (16.8)
61 – 70 years 172 12 (7.0) 160 20 (12.5)
71 – 80 years 282 23 (8.2) 259 43 (16.6)
> 80 years 387 47 (12.1) 340 35 (10.3)
Sex (N = 954)
Male 518 49 (9.5) 469 64 (13.7)
Female 436 40 (9.2) 396 52 (13.1)
Previous history HF (N = 876) 514 50 (9.7) 464 51 (11.0)*
Prior MI (N = 945) 322 29 (9.0) 293 35 (12.0)
COPD, bronchitis, emphysema (N = 944) 188 26 (13.8)* 162 32 (19.8)*
Hypertension (N = 950) 577 49 (8.5) 528 68 (12.9)
Diabetes (N = 952) 221 20 8 (9.0) 201 34 (16.9)
Current smoker (N = 930) 141 13 (9.2) 128 24 (18.8)*
Symptoms and findings
PND (N = 608) 163 9 (5.5) 154 24 8 (15.6)
DOE (N = 849) 672 49 (7.3) 623 80 (12.8)
Orthopnea (N = 655) 330 22 (6.7) 308 43 (14.0)
Leg edema (N = 791) 438 39 (8.9) 399 55 (13.8)
Pulmonary rales (N = 815) 508 35 (6.9) 473 53 (11.2)
S3 gallop (N = 757) 39 2 (5.1) 37 3 (8.1)
JVD (N = 700) 236 20 (8.5) 216 31 (14.4)
Atrial fibrillation (N = 797) 221 9 (4.1) 212 24 (11.3)
HF : Heart Failure; MI: Myocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease; PND: Paroxystal Nocturnal Dyspnea; DOE: 
Dyspnea On Exertion; JVD: Jugular Venous Distension
*p value < 0.05BMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
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2.58) for anemia and 1.14 (95% CI 0.67 to 1.93) for CKD.
In these models, the interaction terms between anemia
and CKD lacked statistical significance.
Discussion
In this study, both anemia and chronic kidney disease
were highly prevalent among HF patients discharged from
two university hospitals and independently associated
with an increased risk of dying in the hospital or of being
readmitted within 30 days. The association between CKD,
anemia and these outcomes (inhospital mortality and
readmission) in HF patients has not been reported previ-
ously. Most studies have focused only on survival after
hospital discharge as an outcome.
One study, in the framework of the SOLVD study,
included only patients with left ventricular dysfunction.
The risk of increased mortality associated with a 1%
reduction in hematocrit was 2.7% [22]. These results were
comparable to another study conducted among Medicare
beneficiaries in community hospitals in the US. In this lat-
est study, patients with left ventricular diastolic dysfunc-
tion were also included as patients with left ventricular
systolic dysfunction. The risk of death associated with a
1% reduction in hematocrit was 2% [23]. In a new large
recent study, among HF patients, chronic kidney disease
and anemia were found independently to confer a two-
fold increased risk of death [25]. Silverberg et al. recently
reported that, in a randomized trial of 32 ambulatory HF
patients with NYHA class III and IV and an hemoglobin <
12 g/dL, the correction of anemia was associated with an
improved functional status and decreased hospitalization.
However, the major limitation of this study was its small
sample size and the fact that the randomization was not
blinded [26]. These observations suggest that anemia is a
clinically important risk factor for death and readmission
among heart failure patients, with or without CKD. The
clinical implication of these findings for patients with HF
is that failure to correct severe anemia among patients
with CKD confers a preventable burden of reduced quality
of life, while clinical trials have demonstrated that correc-
tion of anemia improved these measures. HF patients
should be carefully examinated for presence of CKD and
anemia and, if present, treated according to current evi-
dence [27]. Treating anemia among inpatients with HF
and CKD may then reduce inhospital mortality and early
readmission. However, currently no large clinical trials
have been conducted to evaluate the effect of erythropoi-
etin therapy on survival or readmission among patients
suffering from HF and CKD.
Table 5: Hospital Characteristics in Patients with Heart Failure by Outcome Indicators, N = 955
Inhospital mortality N = 955 30 day readmission N = 866
Patients Characteristics N N dead (%) 89 (9.3%) N N Readmitted (%) 116 (13.4%)
Ejection fraction in % (N = 446)
< = 20 77 8 (10.4) 69 7 (10.1)
20–30 128 13 (10.2) 115 20 (17.4)
30–40 108 5 (4.6) 103 12 (11.7)
> 40 133 14 (10.5) 119 23 (19.3)
Left ventricular function (N = 955)
Diastolic dysfunction 412 35 (8.5) 377 54 (14.3)
Systolic dysfunction 267 24 (9.0) 243 37 (15.2)
Undetermined 276 30 (10.9) 246 25 (10.2)
Discharged with ACEI (N = 836) NA NA 532 76 (14.3)
Charlson comorbidity index (N = 955)
0–1 398 26 (6.5) 372 47 (1.6)
2 216 20 (9.3) 196 24 (12.2)
>2 341 43 (12.6)* 298 45 (15.1)
Length of stay (days) (N = 955)
0–6 247 32 (13.0) 215 26 (12.1)
7–12 321 17 (5.3) 304 36 (11.8)
>12 387 40 (10.3)* 347 54 (15.6)
ACEI: Angiotensin Converting Enzyme Inhibitor; CHF: Congestive Heart Failure; NA: not applicable because relates only to patients discharged 
alive.
*p value < 0.05BMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
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In our study we found that, among HF patients, the prev-
alence of CKD was 25% among males and 20% among
females respectively. However, by using this cut-point of a
serum creatinine of ≥ 124 µmol/L for women and ≥ 133
µmol/L for men for defining CKD, we underestimated the
true prevalence of CKD especially among elderly people.
We choose these cut-points based on previous studies
implemented in the USA [23]. Reduced kidney function
occurred frequently in patients with HF. Two studies have
shown that creatinine clearance less than 60 ml/minute
was present in 20 to 50% of HF patients [28,29]. In
another study, which included Medicare beneficiaries
with heart failure hospitalized in community hospitals,
38% had CKD. In this cohort, the prevalence of CKD was
33% in females and 46% in males [23]. Our results are
similar to those found in these studies and show that CKD
is highly prevalent among HF patients.
Interest in the relationship between HF and anemia is
growing. Anemia commonly complicates HF (14–28% of
patients depending on the cut off used) [30] and is a
potential exacerbating factor [31]. In our study the preva-
lence of anemia (hemoglobin < 12 g/dL) among HF
patients was 28%. In another study performed in one
Swiss university hospital, the prevalence of anemia was
15% [13]. Silverberg et al. showed that the prevalence of
anemia increased with the severity of HF and reached
almost 80% in those patients with a NYHA class IV [26].
Anemia observed among individuals with HF is highly
multi-factorial, but, a decreased renal function is a cause
in numerous patients [32].
Anemic patients with chronic renal failure should receive
treatment with recombinant human erythropoietin (r-
HuEPO, Eéoetin) to maintain hemoglobin levels over 11
g/dL with an acceptable target of 12 to 12.5 g/dL, accord-
ing to recommendations from the European practice
guideline for management of anemia in patients with
chronic renal failure [33] and the National Kidney Foun-
dation K/DOQI clinical practice guidelines for anemia of
chronic kidney disease [27]. Benefits of adequate hemo-
globin levels had been established in patients undergoing
dialysis, and are supposed to be relevant also in CKD
patients. In addition, anemic patients should receive iron
supplementation in order to maintain serum ferritin lev-
els above 100 µg/L and transferrin saturation above 20%.
This study had a number of limitations. It is an observa-
tional study based on information available in medical
records. The chart abstraction process was implemented
in each hospital by different persons with different educa-
tion and backgrounds, although with similar training.
Then, in one hospital the entire medical chart was availa-
ble to the abstractors, whereas in the other only the elec-
tronic discharge letter, laboratory findings and reports
from cardiology testing were available. In addition, the
quality of medical records and completeness of informa-
tion may also vary between centers. Incorrect information
may have led to some misclassification bias. Further this
study was conducted on an opportunity sample of two
hospitals, making the generalisibility of results uncertain.
Then, we excluded patients with valvular heart disease
and acute myocardial infarction, because it was our intent
to focus on a homogenous group of individuals with
established heart failure. However, we agree that the issue
of anemia and outcomes in both of these patient groups
is important. Further, we were not able to exclude other
causes of anemia, including the presence of iron, folate
and vitamin B12 deficiencies, dilutional anemia, and the
anemia of chronic diseases different from CKD, as expla-
nations for anemia observed in this population and per-
haps, to account for some potential confounders. Then,
Table 6: Results of the Logistic Regression Models, N = 910
Parameter Standard Error P Value
Risk Factors
Model for Inhospital Mortality, N = 910
Hemoglobin in g/dL -0.3898 0.1159 0.0008
Serum creatinine in µmol/L -0.0122 0.0088 0.166
Hemoglobin in g/dL × Serum creatinine in µmol/L 0.0021 0.0008 0.008
Length of stay 0.0063 0.0060 0.296
COPD 0.8079 0.2846 0.005
Model for 30 Day Readmission, N = 767
Hemoglobin in g/dL -0.1300 0.0499 0.009
Serum creatinine in µmol/L -0.0008 0.0026 0.744
Hemoglobin in g/dL × Serum creatinine in µmol/L NA NA NA
Age -0.0129 0.0079 0.101
History of heart failure -0.4308 0.2187 0.049
COPD 0.6666 0.2536 0.009
COPD: Chronic Obstructive Pulmonary Disease; NA: not applicable because not statistically significant and therefore not in the final best modelBMC Nephrology 2006, 7:3 http://www.biomedcentral.com/1471-2369/7/3
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given the relative high number of elderly patients in the
study population and that these patients may have CKD
even with normal creatinine value; we underestimated the
true prevalence of CKD. Finally, we acknowledge that we
were not able to measure others risk factors associated
with epo-resistance such as immune activation. We will
consider measuring it in future studies. However, we
would like to emphasis that the concerns about ACEI and
anemia should not keep physicians from using ACE
inhibitors in their management of heart failure.
Conclusion
In conclusion, we found further evidence that the con-
comitant presence of either CKD or anemia increased the
risk of dying in the hospital or of being readmitted within
30 days among patients hospitalized with heart failure.
The association persisted after controlling for other factors
associated with adverse outcomes in these patients.
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